Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Positive Topline Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A DEE Patients
Summary
On September 3, 2024, Praxis Precision Medicines, Inc. announced the topline results from its EMBOLD study evaluating relutrigine (PRAX-562) in patients with SCN2A and SCN8A developmental and epileptic encephalopathy (DEE). The study demonstrated a 46% placebo-adjusted reduction in countable motor seizures. Relutrigine was well-tolerated, with the most common adverse events being infections, vomiting, pyrexia, somnolence, and constipation. Five patients achieved a 28-day seizure-free status, a significant improvement compared to none on placebo. Praxis Precision Medicines plans to initiate an expanded registration cohort and discuss other DEEs with the FDA by Q1 2025.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement